DF/HCC (Dana-Farber/Harvard Cancer Center)
Now in its 18th year of operation, Dana-Farber/Harvard Cancer Center (DF/HCC) was the first consortium model, NCI-designated Comprehensive Cancer Center in the country. The consortium is comprised of 1,100 members from five principal Harvard-affiliated hospitals and two Harvard health science schools: Beth Israel Deaconess Medical Center (BIDMC), Boston Children's Hospital (BCH, Brigham and Women's Hospital (BWH), Dana-Farber Cancer Institute (DFCI), Harvard Medical School (HMS), Harvard T.H. Chan School of Public Health (HSPH), and Massachusetts General Hospital (MGH).
Established in 2008, Harvard Catalyst | The Harvard Clinical and Translational Science Center is dedicated to improving human health by enabling collaboration and providing tools, training, and technologies to clinical and translational investigators. As a shared enterprise of Harvard University, Harvard Catalyst resources are made freely available to all Harvard faculty and trainees, regardless of institutional affiliation or academic degree. Harvard Catalyst is funded by the National Institutes of Health (NIH) Clinical and Translational Science Awards (CTSA) Program.